IDiyas

For the Inventor, By the Inventor

Riehen, Switzerland

Matthias Beat Wittwer

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 11.9

ph-index = 3

Forward Citations = 21(Granted Patents)


Location History:

  • Wuppertal, DE (2018 - 2019)
  • Riehen, CH (2019 - 2022)

Company Filing History:

goldMedal13 out of 378 
 
Bayer Pharma Aktiengesellschaft
 patents
silverMedal6 out of 12,157 
 
Bayer Aktiengesellschaft
 patents
where one patent can have more than one assignee

Years Active: 2018-2022

Loading Chart...
Loading Chart...
14 patents (USPTO):
1. 11472803 - 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof (2022-10-18),
2. 11298367 - Prodrugs of substituted triazole derivatives and uses thereof (2022-04-12),
3. 11173151 - Substituted triazole derivatives and uses thereof (2021-11-16),
4. 11149023 - Substituted triazole derivatives and uses thereof (2021-10-19),
5. 11091463 - Amide-substituted pyridinyltriazole derivatives and uses thereof (2021-08-17),
6. 10927109 - 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof (2021-02-23),
7. 10927098 - Hydroxyalkyl-substituted triazole derivatives and uses thereof (2021-02-23),
8. 10815205 - Amide-substituted phenyltriazole derivatives and uses thereof (2020-10-27),
9. 10526314 - Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof (2020-01-07),
10. 10525041 - Fluoroalkyl-substituted aryltriazole derivatives and uses thereof (2020-01-07),
11. 10519154 - 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof (2019-12-31),
12. 10472348 - Amide-substituted pyridinyltriazole derivatives and uses thereof (2019-11-12),
13. 10435403 - Positive allosteric modulators of muscarinic M2 receptor (2019-10-08),
14. 9988367 - Amide-substituted pyridinyltriazole derivatives and uses thereof (2018-06-05),

Title: Matthias Beat Wittwer: A Pioneer in Pharmaceutical Innovations

Introduction

Matthias Beat Wittwer, an esteemed inventor based in Riehen, Switzerland, has made significant contributions to the field of pharmaceutical research and development. With a remarkable portfolio of 14 patents, his work primarily focuses on innovative medicinal compounds aimed at treating various diseases, particularly cardiovascular and renal disorders.

Latest Patents

Among his latest patents, Wittwer has developed novel 7-substituted 1-arylnaphthyridine-3-carboxamides. These compounds are designed for the treatment and prevention of diseases, specifically targeting cardiovascular and renal disorders. Another notable invention is his work on prodrugs of substituted triazole derivatives, which offers potential treatments for similar health issues. The applications of these compounds highlight his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Matthias Wittwer's career has been significantly shaped by his association with prominent pharmaceutical companies such as Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft. His involvement in these organizations has provided him with the platform to collaborate on cutting-edge research and contribute to groundbreaking advancements in medicinal chemistry.

Collaborations

Throughout his career, Wittwer has had the opportunity to work alongside distinguished colleagues, including Hanna Tinel and Thomas Neubauer. These collaborations have fostered a dynamic exchange of ideas and expertise, further enhancing the innovation stemming from his projects.

Conclusion

In summary, Matthias Beat Wittwer is a remarkable inventor whose extensive research and patent portfolio reflect his dedication to improving healthcare. His innovative work in developing novel pharmaceutical compounds holds the potential to make a significant impact on the treatment and prevention of serious health conditions, underscoring his importance in the field of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…